Details

Autor(en) / Beteiligte

• Hammer, Scott M
• Sobieszczyk, Magdalena E
• Janes, Holly
• Karuna, Shelly T
• Mulligan, Mark J
• Grove, Doug
• Koblin, Beryl A
• Buchbinder, Susan P
• Keefer, Michael C
• Tomaras, Georgia D
• Frahm, Nicole
• Hural, John
• Anude, Chuka
• Graham, Barney S
• Enama, Mary E
• Adams, Elizabeth
• DeJesus, Edwin
• Novak, Richard M
• Frank, Ian
• Bentley, Carter
• Ramirez, Shelly
• Fu, Rong
• Koup, Richard A
• Mascola, John R
• Nabel, Gary J
• Montefiori, David C
• Kublin, James
• McElrath, M. Juliana
• Corey, Lawrence
• Gilbert, Peter B

Titel

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

Ist Teil von

• The New England journal of medicine, 2013-11, Vol.369 (22), p.2083-2092

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In an efficacy trial, 2504 persons at high risk for HIV-1 acquisition received either a DNA prime–recombinant adenovirus type 5 boost (DNA/rAd5) vaccine or placebo. The vaccine regimen did not reduce either HIV-1 acquisition or viral load. The epidemic infection caused by the human immunodeficiency virus type 1 (HIV-1) is now in its fourth decade, with an estimated 2.5 million new infections occurring annually worldwide. 1 The number of newly infected persons, although diminishing, outpaces the number of patients who initiate antiretroviral therapy. Despite a number of successful prevention interventions that have been reported, including preexposure prophylaxis and treatment as prevention, 2 – 9 ultimate control of the HIV epidemic will most likely come only with the development of a safe and effective preventive vaccine. This goal has proved to be elusive. Of the efficacy trials of HIV vaccines that . . .